Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA (lomitapide) Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH) (The Manila Times) - Jun 4, 2026 - "The EC approval is based on evidence from a Phase 3, open-label, single-arm, multicentre study evaluating lomitapide in 43 pediatric participants aged 5 to 17 years with HoFH. The APH-19 study achieved its primary endpoint, demonstrating a mean 53.5% reduction in LDL‑C from baseline at week 24"
EMA approval • Homozygous Familial Hypercholesterolemia
|